世界の幹細胞（ステムセル）治療に関する制度動向、パイプライン分析、市場予測（～2020）...市場調査レポートについてご紹介

Table of Contents

1 INTRODUCTION
1.1 Objectives
1.2 Markets Covered
1.3 Stakeholders
1.4 Market Size Estimation
1.4.1 Market Definition
1.4.2 Market Scope
1.5 Research Methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.5.3 Analysis & Output
1.5.4 Assumptions
1.5.5 Limitations
1.5.6 Key Data Points Taken From Secondary Sources
1.5.7 Key Data Points Taken From Primary Sources

2 EXECUTIVE SUMMARY

3 MARKET DYNAMICS
3.1 Introduction
3.2 Drivers
3.2.1 Increasing Funding for New Stem Cell Lines
3.2.2 Development of Advanced Genomic Methods for Stem Cell Analysis
3.2.3 Increasing Focus on Human Embryonic Stem Cells
3.2.4 Increasing Approvals of Clinical Trials for Stem Cells Therapy
3.3 Restraints
3.3.1 Lack of Required Infrastructures
3.3.2 Difficulties Related with the Preservation Of Stem Cells
3.3.3 Ethical Issues Related to Embryonic Stem (ES) Cell
3.3.4 Immunorejection After Stem Cell Transplantation
3.3.5 Complexity Involved in Identification of Stem Cells in Adult Tissues
3.4 Opportunities
3.4.1 Lack of Effective Treatments to Cure Diseases
3.4.2 Evolution of New Stem Cell Therapies
3.4.3 Emergence of Induced Pluripotent Stem (IPS) Cells as an Alternative to Escs
3.4.4 Emerging Markets Unfolds New Avenues due to Low Regulatory Barriers and Clinical Trial Cost
3.5 Challenges
3.5.1 Dearth of Reimbursements
3.5.2 High Costs Incurred in Stem Cell Processing
3.5.3 Need of Automated Cell Culturing
3.5.4 Lack of Clear Regulatory Guidelines
3.6 Winning Imperatives
3.6.1 Partnering With Academic Institutes
3.6.2 Collaborating With Giant Pharmaceutical Firms
3.6.3 High Focus on Emerging Markets
3.7 Burning Issues
3.7.1 Establishment of Safety Profiles for Stem Cell Therapy
3.7.2 Granting Orphan Drug Status to Stem Cell Therapeutics

4 PIPELINE ANALYSIS

5 INVESTOR NETWORK

6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY
6.1 Introduction
6.2 Allogeneic Stem Cell Therapy Market, By Application
6.2.1 Introduction
6.2.2 Eye Diseases
6.2.3 GIT diseases
6.2.4 Immune System Diseases
6.2.5 Metabolic Diseases
6.2.6 Musculoskeletal Disorders
6.2.7 CNS Diseases
6.2.8 CVS Diseases
6.2.9 Wounds and Injuries
6.2.10 Other Diseases
6.3 Autologous Stem Cell Therapy, By Application
6.3.1 Introduction
6.3.2 GIT diseases
6.3.3 CNS Diseases
6.3.4 Musculoskeletal Disorders
6.3.5 Wounds and Injuries
6.3.6 CVS Diseases
6.3.7 Other Diseases

7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS
7.1 Introduction
7.2 Eye Diseases
7.3 GIT diseases
7.4 Immune System Diseases
7.5 Metabolic Diseases
7.6 Musculoskeletal Disorders
7.7 CNS Diseases
7.8 CVS Diseases
7.9 Wounds and Injuries
7.10 Other Diseases

8 REGULATORY LANDSCAPE
8.1 North America
8.2 Asia-Pacific
8.3 Europe
8.4 RoW (Rest of the World)

9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia-Pacific
9.5 RoW (Rest of the World)

10 COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Competitive Situation & Trends

11 COMPANY PROFILES
11.1 Aastrom Biosciences Inc.
11.2 Advanced Cell Technologies, Inc.
11.3 Athersys Inc.
11.4 Celgene Corporation
11.5 Cellular Dynamics International
11.6 Cytori Therapeutics, Inc.
11.7 Fibrocell Science, Inc.
11.8 Gamida Cell Ltd.
11.9 Mesoblast Ltd.
11.10 Pluristem Therapeutics Inc.
11.11 StemCells Inc.